Specialty Pharma Firm RVL Pharmaceuticals Subsidiaries File for Bankruptcy
Portfolio Pulse from Vandana Singh
RVL Pharmaceuticals plc's (NASDAQ:RVLP) operating subsidiaries are filing for bankruptcy in a prepackaged deal with lender Athyrium Capital. The reorganization will allow the RVL subsidiaries to reduce debt, streamline operations, and position themselves under new ownership. RVL's public equity is expected to be canceled upon completion of its wind-down, anticipated during 2024, likely resulting in no recovery to public shareholders. RVLP shares are down 65.2% at $0.05 on the last check Thursday.
October 12, 2023 | 6:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RVL Pharmaceuticals is filing for bankruptcy, which will likely result in no recovery for public shareholders. The company's shares are down 65.2%.
The bankruptcy filing and the expected cancellation of RVL's public equity will likely result in no recovery for public shareholders. This negative news has already impacted the company's stock price, which is down 65.2%.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100